GlassScriptPhysician profile
Walter J Doty
NPI 1518160605
$11,869.93
in general payments reported to CMS, 2019-2025
35 companies · $5,103 in 2025
The $5,103 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,383 · 2020: $1,200 · 2021: $1,485 · 2022: $963 · 2023: $813 · 2024: $922 · 2025: $5,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $2,075 · Travel and Lodging: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $2,074.98 |
| Travel and Lodging | $763.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,975.35 | 2024-2025 | |
| Glaxosmithkline, LLC. | $2,085.06 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,104.99 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Astrazeneca Pharmaceuticals LP | $882.57 | 2019-2024 | Tezspire |
| Insmed, INC. | $401.14 | 2019-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $287.10 | 2019-2022 | |
| Philips North America LLC | $221.51 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $211.39 | 2019-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $176.99 | 2020-2024 | Glassia |
| Genentech USA, INC. | $173.54 | 2019-2022 | |
| Amgen INC. | $148.60 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $144.01 | 2020-2021 | |
| Genzyme Corporation | $137.08 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $120.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $114.09 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $108.40 | 2021-2024 | Ubrelvy, Qulipta |
| Sunovion Pharmaceuticals INC. | $77.66 | 2019-2020 | |
| Circassia INC. | $76.72 | 2019-2020 | |
| Mylan Specialty L.P. | $56.85 | 2019-2023 | Yupelri |
| Fisher & Paykel Healthcare INC | $43.24 | 2022 | |
| Eisai INC. | $36.40 | 2020 | |
| Shire North American Group INC | $28.92 | 2019 | |
| Insulet Corporation | $27.59 | 2019 | |
| Daiichi Sankyo INC. | $23.42 | 2022 | |
| Allergan, INC. | $23.12 | 2020 | |
| Jazz Pharmaceuticals INC. | $21.95 | 2021 | |
| Axsome Therapeutics, INC. | $21.26 | 2023 | Sunosi |
| Melinta Therapeutics, LLC | $20.89 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.92 | 2023 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $19.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.45 | 2021 | |
| United Therapeutics Corporation | $16.41 | 2019 | |
| Pulmonx Corporation | $16.08 | 2020 | |
| Veran Medical Technologies, INC. | $15.61 | 2019 | |
| Tactile Systems Technology INC | $15.41 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.